



Curis, Inc.
Investor Relations Department
4 Maguire Road
Lexington, MA 02421
United States

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: CRIS

Last Trade:	0.84
Trade Time:	4:00 PM ET Dec 8, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	0.79 - 3.48
Volume	100

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its proprietary targeted cancer programs, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com.... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Dec 1, 2017*
[Curis Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & Exposition](#)
- Nov 7, 2017*
[Curis Reports Third Quarter 2017 Financial Results](#)
- Nov 3, 2017*
[Curis to Present at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit](#)
- Nov 1, 2017*
[Curis to Release Third Quarter 2017 Financial Results and Hold Conference Call on November 7, 2017](#)
- Sep 22, 2017*
[Curis to Present at the Cantor Fitzgerald Global Healthcare Conference](#)

Upcoming Events [\[View all \]](#)

- Dec 13, 2017*
[Guggenheim Securities Annual Boston Healthcare Conference](#)
- Events** [\[View all \]](#)
- Financials** [\[View all \]](#)
- [Third Quarter Financial Results](#)
- Mar 9, 2017*
[Annual Report \(10-K\)](#)
- Apr 4, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 7, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 3, 2017*
[Quarterly Report \(10-Q\)](#)
- May 4, 2017*
[Quarterly Report \(10-Q\)](#)